With positive trial results, Bristol Myers looks to widen use of blood disease drug

Bristol Myers Squibb’s blood disease drug Reblozyl helped patients with low- and intermediate-risk myelodysplastic syndrome better than an older anemia treatment, the company said Monday. The positive trial results are a sign that Bristol Myers could soon expand use of the drug, which it believes could reach sales of $4 billion a year.